Form 4: Moderna Director Noubar Afeyan Sells Shares Under 10b5-1 Trading Plan

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on May 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 8, 2024, Noubar Afeyan, a director of Moderna, sold a total of 15,000 shares of common stock.
• The sales were executed in multiple transactions at weighted average prices of $120.3705, $121.586, and $122.0689.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
• Following the reported transactions, Afeyan directly owns 2,011,931 shares of Moderna common stock.
• Afeyan also has indirect ownership through Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. (9,662,114 shares) and Flagship Pioneering, Inc. (3,924 shares).
• Afeyan disclaims beneficial ownership of shares held by Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc. except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document itself is neutral, reporting routine insider sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Risks

• Sales by insiders, even under 10b5-1 plans, can sometimes be perceived negatively by the market.

Future Outlook

The document does not contain any specific forward-looking statements regarding Moderna's future performance.

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares in a predetermined manner, avoiding accusations of trading on non-public information. Investors often monitor insider activity for signals about a company's prospects, but these sales under 10b5-1 plans are generally viewed as less informative than discretionary trades.

Comparison to Industry Standards

• Comparing Moderna to other large-cap biotechnology companies like Pfizer (PFE) or BioNTech (BNTX), insider trading activity is a common occurrence.
• However, the volume and frequency of insider transactions can vary significantly based on individual circumstances and company performance.
• For example, if we compare this to a similar filing from a Pfizer director, we might look at the size of the transaction relative to their overall holdings and the stated purpose of the sale (e.g., diversification, tax planning).

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates